United States - English - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - calcium carbonate (unii: h0g9379fgk) (calcium cation - unii:2m83c4r6zb) - calcium carbonate 1250 mg

United States - English - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - anastrozole (unii: 2z07myw1az) (anastrozole - unii:2z07myw1az) - anastrozole 1 mg

United States - English - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - perindopril erbumine (unii: 1964x464oj) (perindoprilat - unii:2uv6znq92k) - perindopril erbumine 2 mg - perindopril erbumine is indicated for the treatment of patients with essential hypertension. perindopril erbumine may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. perindopril erbumine is indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction. perindopril erbumine can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. perindopril erbumine is contraindicated in patients known to be hypersensitive (including angioedema) to this product or to any other ace inhibitor. perindopril erbumine is also contraindicated in patients with hereditary or idiopathic angioedema. do not co-administer aliskiren with perindopril erbumine in patients with diabetes [see drug interactions (7.8) ]. perindopril erbumine is contraindicated in combination with neprilysin inhibitor (e.g., sacubitril).

United States - English - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - megestrol acetate (unii: tj2m0fr8es) (megestrol - unii:ea6ld1m70m) - megestrol acetate 20 mg - megestrol acetate is indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (i.e., recurrent, inoperable, or metastatic disease). it should not be used in lieu of currently accepted procedures such as surgery, radiation, or chemotherapy. history of hypersensitivity to megestrol acetate or any component of the formulation.

United States - English - NLM (National Library of Medicine)

west-ward pharmaceuticals corp - prednisone (unii: vb0r961hzt) (prednisone - unii:vb0r961hzt) - prednisone 5 mg - prednisone tablets, usp are indicated in the following conditions: endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), ankylosing spondylitis, acute and subacute bursitis, acute nonspecific tenosynovitis, acute gouty arthritis, post-traumatic osteoarthritis, synovitis of osteoarthritis, epicondylitis. collagen diseases during an exacerbation or as maintenance therapy in selected cases of: systemic lupus er

United States - English - NLM (National Library of Medicine)

west-ward pharmaceuticals corp - ondansetron hydrochloride (unii: nmh84ozk2b) (ondansetron - unii:4af302esos) - ondansetron 2 mg in 1 ml - ondansetron injection, usp is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. ondansetron is approved for patients aged 6 months and older. ondansetron injection, usp is indicated for the prevention of postoperative nausea and/or vomiting. as with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/‌or vomiting will occur postoperatively. in patients in whom nausea and/or vomiting must be avoided postoperatively, ondansetron injection, usp is recommended even when the incidence of postoperative nausea and/or vomiting is low. for patients who do not receive prophylactic ondansetron injection, usp and experience nausea and/or vomiting postoperatively, ondansetron injection, usp may be given to prevent further episodes. ondansetron injection, usp is approved for patients aged 1 month and older. ondansetron injection is contraindica

United States - English - NLM (National Library of Medicine)

west-ward pharmaceuticals corp - palonosetron hydrochloride (unii: 23310d4i19) (palonosetron - unii:5d06587d6r) - palonosetron .25 mg in 2 ml - palonosetron hydrochloride (hcl) injection is indicated for: •     moderately emetogenic cancer chemotherapy – prevention of acute and delayed nausea and vomiting associated with initial and repeat courses •     highly emetogenic cancer chemotherapy – prevention of acute nausea and vomiting associated with initial and repeat courses palonosetron hcl injection is contraindicated in patients known to have hypersensitivity to the drug or any of its components [see adverse reactions (6.2)] . r i sk summary there are no available data on palonosetron hcl use in pregnant women to inform a drug-associated risk. in animal reproduction studies, no effects on embryo-fetal development were observed with the administration of oral palonosetron hcl to rats and rabbits during organogenesis at doses up to 1894 and 3789 times the recommended human intravenous dose, respectively [see data]. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown.  in the u.s. general popula

United States - English - NLM (National Library of Medicine)

west-ward pharmaceuticals corp - paricalcitol (unii: 6702d36og5) (paricalcitol - unii:6702d36og5) - paricalcitol 2 ug in 1 ml - paricalcitol injection is an active vitamin d2 analogue indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (ckd) stage 5. paricalcitol injection is contraindicated in patients with evidence of: - hypercalcemia [see warnings and precautions (5.1) ] - vitamin d toxicity [see warnings and precautions (5.1) ] or - hypersensitivity to paricalcitol or any inactive ingredient in this product [see adverse reactions (6.2) ] pregnancy category c paricalcitol has been shown to cause minimal decreases in fetal viability (5%) when administered daily to rabbits at a dose 0.5 times the 0.24 mcg/kg human dose (based on surface area, mg/m2 ) and when administered to rats at a dose 2 times the 0.24 mcg/kg human dose (based on plasma levels of exposure). at the highest dose tested (20 mcg/kg 3 times per week in rats, 13 times the 0.24 mcg/kg human dose based on surface area), there was a significant increase of the mortality of newborn rats at doses that were mate

United States - English - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron 1 mg - granisetron hydrochloride tablets are indicated for the prevention of: granisetron hydrochloride is contraindicated in patients with known hypersensitivity to the drug or any of its components.

United States - English - NLM (National Library of Medicine)

west-ward pharmaceuticals corp - nicardipine hydrochloride (unii: k5bc5011k3) (nicardipine - unii:cz5312222s) - nicardipine hydrochloride 2.5 mg in 1 ml - nicardipine hydrochloride injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable. for prolonged control of blood pressure, transfer patients to oral medication as soon as their clinical condition permits [see dosage and administration (2.6)]. do not use nicardipine in patients with advanced aortic stenosis because of the afterload reduction effect of nicardipine. reduction of diastolic pressure in these patients may worsen rather than improve myocardial oxygen balance. pregnancy category c. there are no adequate and well-controlled studies of nicardipine use in pregnant women. there are limited human data in pregnant women with pre-eclampsia and preterm labor. in animal reproduction and developmental toxicity studies, evidence of fetal harm was observed. therefore use nicardipine during pregnancy only if the potential benefit justifies the potential risk to the fetus. in reproduction studies conducted in rats and rabbits, increased embryolethality oc